Home Featured 2

Featured 2

Featured posts

Most popular

Ki-67 in Pulmonary Neuroendocrine Tumors: Where Do We Stand?

lungcanc

Artificial Intelligence in Lung Cancer: Opening New Avenues for Detection, Diagnosis, and Prognostication

Smoking Cessation Prior to Lung Cancer Surgery

Lung Cancer in the Brazilian Health System: Screening, Drug Approvals, Barriers to Care, and Success Stories

Financial Incentives and Free Treatment Aids for Smoking Cessation in the Workplace

Increasing the Role of Local Consolidation in Oncogenic-Driven Advanced NSCLC

lungcanc

IASLC Journals Share Exciting Milestones on Metrics Journeys

lungcanc

Consolidating Gains with Chemotherapy in SCLC Maintenance Trials: A Discussion with...

lungcanc

Histologic Transformation From NSCLC to SCLC: A Mechanism of Resistance to...

lungcanc

Adjuvant EGFR-TKI for Resected NSCLC: Who, When, and Where?

lungcanc

Timing of Immune Checkpoint Inhibitors With Respect to Molecular Testing in...

lungcanc

Understanding the Effects of Time to Surgery on Upstaging for Stage...

lungcanc

Treating Patients with MET Alterations: A Q&A with Dr. Ravi Salgia

lungcanc

Ireland’s Complex Healthcare System and Its Relation to Innovative Ways for...

lungcanc

Expanding Efforts Help Address Disparities in Lung Cancer Care

lungcanc

12 3...7 Page 1 of 7

Meeting News

Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation

Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation

TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse

cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib